Ticker

No recent analyst price targets found for TLTFF.

Latest News for TLTFF

Theralase(R) Receives Receipt for C$100 Million Base Shelf Prospectus

Toronto, Ontario--(Newsfile Corp. - June 30, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that it has filed and obtained a receipt for a final base shelf…

Newsfile Corp • Jun 30, 2026
Theralase(R) Lists Warrants on the TSXV

Toronto, Ontario--(Newsfile Corp. - June 3, 2026) - Theralase Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase" or the "Company"), a clinical stage

Newsfile Corp • Jun 3, 2026
Theralase(R) Releases Q1 2026 Financial Statements

Theralase(R) Provides an Update on its Phase II Bladder Cancer Clinical Study Toronto, Ontario--(Newsfile Corp. - May 29, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of various cancer, bacteria and viruses has…

Newsfile Corp • May 29, 2026
Theralase(R) Closes C$4.8 Million Offering

Toronto, Ontario--(Newsfile Corp. - May 20, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses is pleased to announce that it has closed its previously announced brokered private…

Newsfile Corp • May 20, 2026

🧮 Earnings Move Analyzer

Insider Trading

No insider trades found for TLTFF.

No Senate trades found for TLTFF.

No House trades found for TLTFF.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top